Drug Profile
Research programme: membrane protein-targeting antibodies - AstraZeneca/MSM Protein Technologies
Latest Information Update: 06 Aug 2021
Price :
$50
*
At a glance
- Originator Cambridge Antibody Technology; MSM Protein Technologies
- Developer AstraZeneca; MSM Protein Technologies
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bacterial infections; Viral infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Viral-infections in USA (Parenteral)
- 29 Feb 2008 Preclinical development is ongoing